Analyses of Cerebrospinalfluid in Patients With Delirium
Status
Conditions
Treatments
Details and patient eligibility
About
The current project aims to measure biomarkers in the cerebrospinalfluid (CSF) and serum samples from patients with delirium. We hope to uncover new insights into the pathophysiology of delirium and explore its link to dementia.
Full description
Delirium is a common and serious complication to acute illness, and is characterized by acute disturbances in attention, awareness, and cognition. Dementia is a major risk factor of delirium, and delirium increases the risk of dementia progression and development. As the conditions share both clinical and epidemiological features, some researchers suggest that also pathophysiological links are shared. Understanding delirium pathophysiology, which is poorly understood, may thus help elucidate early molecular mechanisms in dementia.
This study aims to to increase our understanding of the pathophysiology of delirium and molecular links between delirium and dementia, by exploring cerebrospinal fluid (CSF) biomarkers.
Enrollment
Sex
Volunteers
Inclusion criteria
- Patients with acute hip fracture
Exclusion criteria
- Moribund patients.
- Lack of consent
Trial contacts and locations
Loading...
Central trial contact
Leiv O Watne, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal